Metamizol Heumann (Metamizole Sodium Monohydrate)

Metamizole works by non‑selectively inhibiting cyclo‑oxygenase enzymes, reducing prostaglandin production, and by stimulating descending inhibitory pathways in the central nervous system. These actions together provide analgesic and antipyretic effects.

The appropriate dose of Metamizol Heumann is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Dosing instructions are provided on the prescription label and should be followed exactly.

Safety of Metamizole in pregnancy and lactation has not been firmly established. It is generally avoided unless the potential benefit justifies the possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Metamizol Heumann, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizole is a non‑opioid analgesic that offers strong pain relief and antipyretic activity, often considered when NSAIDs or paracetamol are insufficient. Unlike many NSAIDs, it has a lower risk of gastrointestinal ulceration but carries a rare risk of agranulocytosis, which requires blood‑count monitoring.

Metamizol Heumann should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Metamizol Heumann is administered orally. The tablets (or oral formulation) should be swallowed whole with a full glass of water, unless otherwise directed by the prescriber. It is taken with or without food, according to individual tolerance.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, rash, or breathing difficulties, and seek immediate medical attention if they occur.

Metamizol Heumann should be avoided in individuals with known hypersensitivity to Metamizole or other sulfonamide drugs, those with a history of blood dyscrasias, severe liver or kidney disease, and in pregnant or breastfeeding women unless the prescriber determines that the benefits outweigh the risks.